Anne T. Knisely

Sep 6, 2024 | digitalcommons.library.tmc.edu | Rodabe N. Amaria |Anne T. Knisely |David Vining |Scott Kopetz

BACKGROUND: Tumor-infiltrating lymphocyte (TIL) therapy has shown efficacy in metastatic melanoma, non-small cell lung cancer, and other solid tumors. Our preclinical work demonstrated more robust CD8 predominant TIL production when agonistic anti-4-1BB and CD3 antibodies were used in early ex vivo TIL culture. METHODS: Patients with treatment-refractory metastatic colorectal (CRC), pancreatic (PDAC) and ovarian (OVCA) cancers were eligible.

Feb 1, 2024 | jitc.bmj.com | Rodabe N. Amaria |Anne T. Knisely |David Vining |Scott Kopetz

MethodsMale and female patients between the ages of 18 and 70 years old with recurrent/refractory high-grade non-mucinous OVCA, CRC, or oligometastatic PDAC with an area of tumor amenable to excisional biopsy were considered for enrollment. For the OVCA cohort, patients were required to have failed at least two prior lines of chemotherapy or have platinum-resistant disease.